Drug Trial Radar · NCT07007065
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
561
Planned (sponsor's estimate)
Start
Nov 5, 2025
Primary completion
Mar 2033
Study completion Mar 2033
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD). Surabgene Lomparvovec (ABBV-RGX-314) is an investigational gene therapy being developed for the treatment of neovascular age-related macular degeneration (nAMD). Participants will be placed into 1 of 3 groups, called treatment arms. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis of previously treated nAMD will be enrolled. Around 561 participants will be enrolled in the study at approximately 150 sites worldwide. Participants in groups 1 and 2 will receive a single subretinal dose of ABBV-RGX-314. Participants in group 3 will receive Ranibizumab as needed throughout the study. Ranibizumab will be given as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection), and ABBV-RGX-314 will be given as a subretinal (between the retina and the back of the eye) injection. The Assessment Period begins after randomization (1:1:1) to one of the ABBV-RGX-314 treatment groups or control at Week -2 and lasts up to 5 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
Surabgene Lomparvovec (ABBV-RGX-314)Drug
subretinal injection
Ranibizumab ControlDrug
intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized intravitreal anti-VEGF injection rateTime frame: Up to Week 54
- Number of Participants Experiencing Adverse EventsTime frame: Up to 5 years
Locations
138 sites in 17 countries. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center - Mesa /ID# 279265
Mesa, Arizona · Recruiting
American Vision Partners /ID# 264615
Sun City, Arizona · Recruiting
Retinal Diagnostic Center /ID# 263054
Campbell, California · Recruiting
The Retina Partners /ID# 263265
Encino, California · Recruiting
Retina Associates of Southern California /ID# 263056
Huntington Beach, California · Recruiting
Shiley Eye Institute At Uc San Diego Health /ID# 276682
La Jolla, California · Recruiting
Northern California Retina Vitreous Associates - Mountain View /ID# 263990
Mountain View, California · Recruiting
Eye Research Foundation /ID# 277345
Newport Beach, California · Recruiting
Retina Consultants of San Diego /ID# 264026
Poway, California · Recruiting
Retina Consultants Of Southern California - Redlands /ID# 276496
Redlands, California · Recruiting
Kaiser Permanente - Riverside Medical Center /ID# 263253
Riverside, California · Recruiting
Retinal Consultants - Sacramento - Greenback Lane /ID# 263983
Sacramento, California · Recruiting
UCSF, Wayne and Gladys Valley Center for Vision /ID# 263058
San Francisco, California · Recruiting
Orange County Retina Medical Group /ID# 266612
Santa Ana, California · Recruiting
Retina Consultants of Southern Colorado /ID# 263284
Colorado Springs, Colorado · Recruiting
Colorado Retina Associates /ID# 263247
Lakewood, Colorado · Recruiting
Advanced Vision Surgery Center /ID# 264208
Longmont, Colorado · Recruiting
Advanced Research, LLC /ID# 276526
Deerfield Beach, Florida · Recruiting
Segal Drug Trials, Inc /ID# 276966
Delray Beach, Florida · Recruiting
Retina Vitreous Consultants LLP business DBA as Retina Group of Florida /ID# 264631
Fort Myers, Florida · Recruiting
Florida Retina Institute - Orlando /ID# 263288
Orlando, Florida · Recruiting
Center for Retina and Macular Disease /ID# 264201
Winter Haven, Florida · Recruiting
Southeast Retina Center /ID# 263264
Augusta, Georgia · Recruiting
Vision Medical Research /ID# 277102
Oak Lawn, Illinois · Recruiting
Springfield Clinic Main Campus /ID# 265202
Springfield, Illinois · Recruiting
Retina Partners Midwest, P.C. /ID# 264031
Carmel, Indiana · Recruiting
Wolfe Eye Clinic - West Des Moines /ID# 263270
West Des Moines, Iowa · Recruiting
Retina Associates - Lenexa /ID# 264607
Lenexa, Kansas · Recruiting
Maine Eye Center - Marginal Way Campus /ID# 263251
Portland, Maine · Recruiting
The Retina Care Center /ID# 263263
Baltimore, Maryland · Recruiting
Retina Specialist /ID# 264633
Towson, Maryland · Recruiting
Associated Retinal Consultants /ID# 263289
Royal Oak, Michigan · Recruiting
Retina Consultants of Minnesota (RCM) - Edina Retina Clinic /ID# 279427
Edina, Minnesota · Recruiting
Mayo Clinic - Minnesota /ID# 263977
Rochester, Minnesota · Recruiting
Retina Institute - St. Louis /ID# 263985
St Louis, Missouri · Recruiting
Sierra Eye Associates /ID# 263240
Reno, Nevada · Recruiting
Monmouth Retina Consultants /ID# 279252
Little Silver, New Jersey · Recruiting
Cleveland Clinic - Cleveland /ID# 264210
Cleveland, Ohio · Recruiting
Ohio State Havener Eye Institute - Columbus /ID# 263987
Columbus, Ohio · Recruiting
Midwest Retina /ID# 263231
Dublin, Ohio · Recruiting
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.